US-based medical technology company Haemonetics has reached an agreement to sell the wholly owned subsidiary Inlog Holdings France to French private equity company Abénex.
Inlog Holdings France develops and sells blood bank and hospital software solutions through its subsidiary In Log. The products are used mainly in France and in several other countries outside of the US.
Haemonetics president and CEO Chris Simon said: “This divestiture and the recent sale of our US blood donor software help shift our portfolio toward our growth segments. Software that supports our growth and sector leadership remains an important part of our innovation agenda.”
As part of the transaction, Abénex will acquire Haemonetics’ ownership interest in Inlog Holdings France and In Log. This covers the ownership transfer of products, including the EdgeSuite software solutions such as EdgeBlood, EdgeCell, EdgeTrack and EdgeLab, and SapaNet software solution.
These products are designed to suit the operational needs of blood banks and blood centres. They optimise workflow efficiencies in hospital labs to increase patient safety and streamline lab processes.
Abénex director Thomas Peretti said: “We are enthusiastic about continuing what Haemonetics and the Inlog team have achieved over the last decade.
“We will rely on Inlog’s team to better serve its clients by investing in innovation and in people. We are convinced that Inlog has strong assets to grow within the European market.”
Subject to customary closing conditions, the transaction is expected to close in the third quarter of this year.
Last month, Haemonetics announced the sale of its Fajardo, Puerto Rico, manufacturing operations to GVS.
In May, the company entered a definitive agreement to sell certain blood donor management software solution assets within its Blood Center business unit to the GPI Group.